Thumbnail Image
Publication

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial.

Waddell, T
; 
Chau, I
; 
Cunningham, D
; 
Gonzalez, D
; 
Frances, A
; 
Okines, C
; 
Wotherspoon, A
; 
Saffery, C
; 
Middleton, G
; 
Wadsley, J
... show 10 more
Citations
Altmetric:
Abstract
EGFR overexpression occurs in 27-55% of oesophagogastric adenocarcinomas, and correlates with poor prognosis. We aimed to assess addition of the anti-EGFR antibody panitumumab to epirubicin, oxaliplatin, and capecitabine (EOC) in patients with advanced oesophagogastric adenocarcinoma.
Authors
Waddell, T
Chau, I
Cunningham, D
Gonzalez, D
Frances, A
Okines, C
Wotherspoon, A
Saffery, C
Middleton, G
Wadsley, J
Ferry, D
Mansoor, Was
Crosby, T
Coxon, F
Smith, D
Waters, J
Iveson, T
Falk, S
Slater, S
Peckitt, C
Barbachano, Y
Affiliation
The Royal Marsden NHS Foundation Trust, London and Surrey, UK.
Description
Date
2013-05
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Article
Citation
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. 2013, 14 (6):481-9 Lancet Oncol
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/295490
Embedded videos